| Vol. 25.15 – 29 April, 2024 |
| |
|
|
| The authors interrogated CAR-T cells targeting HER2 with either low or high affinity in various preclinical models. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists presented a metabolic refueling approach using inosine as an alternative fuel. CAR T cells were engineered to express membrane-bound CD26 and cytoplasmic adenosine deaminase 1 (ADA1), converting adenosine to inosine. [Cell Reports Medicine] |
|
|
|
| Researchers developed a controllable cell therapy where synthetic D-Domain-containing proteins (SparX) bind one or more tumor antigens and mark those cells for elimination by genetically modified T cells [Molecular Therapy] |
|
|
|
| The mosquito-transmitted Nodamura virus was attenuated in mice by mutations that prevent expression of the B2 viral suppressor of RNA interference and consequently, drastically enhance in vivo production of the virus-targeting small-interfering RNAs. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers tested a series of antibodies raised against the CA125 extracellular repeat domain of MUC16 and adapted them to the CAR format. Comparisons between these candidates, and against an existing CAR targeting the MUC16 ectodomain, identified K101 as having high potency and specificity. [Journal for Immunotherapy of Cancer] |
|
|
|
| An injectable tissue engineering scaffold consisting of highly porous microspheres compatible with transplantation of cells was modified to contain the computed tomography contrast agent barium sulphate. [Advanced Healthcare Materials] |
|
|
|
| To identify CD3-specific T cell agonists, several RNA aptamers were selected against CD3 using SELEX combined with high-throughput sequencing. [Molecular Therapy – Nucleic Acids] |
|
|
|
| Investigators explored the possibilities of ependymal repair in germinal matrix hemorrhages/posthemorrhagic hydrocephalus using a combination of neural stem cells, ependymal progenitors, and mesenchymal stem cells. [Stroke] |
|
|
|
| CD8TM.41BBIC-based anti-B cell maturation antigen CAR vectors with either a long linker or a short linker between the light and heavy scFv chain, CD28TM.41BBIC-based and CD28TM.CD28IC-based anti-BCMA CAR vector systems were used in primary human T cells. [Cancer Immunology Immunotherapy] |
|
|
|
|
| The authors compare the effectiveness of 3D suspended fiber scaffolds with 2D culture systems, discussing their respective benefits and limitations in the context of tissue regeneration. [International Journal Of Biological Macromolecules] |
|
|
|
| Scientists highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel. [Expert Review Of Anticancer Therapy] |
|
|
|
|
| Researchers at the University of California, San Francisco (UCSF) have begun enrollment for a clinical trial that uses a new, powerful version of CAR T as a potential therapy for glioblastoma, the most common and deadly adult brain cancer. [Insider Precision Medicine] |
|
|
|
| The Hong Kong Polytechnic University has entered into a formal collaboration with Axis Therapeutics to foster cancer immunotherapy research and development, with the aim of improving cancer treatment for patients in Hong Kong. [Hong Kong Polytechnic University (EurekAlert!)] |
|
|
|
|
| May 31 – June 3, 2024 Valencia, Spain |
|
|
|
|
|
| Johnson & Johnson – Spring House, Pennsylvania, United States |
|
|
|
| Princeton University – Princeton, New Jersey, United States |
|
|
|
| University of Oregon – Eugene, Oregon, United States |
|
|
|
| Monash University – Melbourne, Victoria, Australia |
|
|
|
| Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
|